Due to low commercial sales, Abbott stopped selling the first-generation Absorb Bioresorbable Vascular Scaffold. We pioneered bioresorbable technology because we believe it offers patients the possibility of life without permanent metallic implants, and we will continue work on a next generation bioresorbable device. We'll also continue to follow implanted patients in existing Absorb clinical trials to assess long-term outcomes after the scaffold has dissolved. We're dedicated to developing treatments that help patients with vascular and other heart diseases live their fullest lives.
Q1. What is the announcement?
Due to low commercial uptake, Abbott stopped selling its first-generation Absorb Bioresorbable Vascular Scaffold. Abbott discontinued all sizes of Absorb Bioresorbable Vascular Scaffold System and Absorb GT1 Bioresorbable Vascular Scaffold System as of September 14th 2017. We recognize that BRS technologies offer patients the possibility of life without permanent metallic implants, and we will continue to work on a next generation device while monitoring long-term outcomes after stent resorption in current Absorb trials.
Q2. Does this decision apply to all the geographies?
Yes. Abbott discontinued the Absorb Bioresorbable Vascular Scaffold System and Absorb GT1 Bioresorbable Vascular Scaffold System as of September 14th in all countries.
Q3. What should physicians do with the existing product?
Physicians can implant Absorb with their available inventory if they choose to do so.
Q4. Will Absorb continue to be studied in clinical trials?
Abbott will continue to follow patients in existing clinical studies per protocols.
If you need more information, please contact your local Abbott Vascular representative or customer service team.
Our online product catalogs provide the very latest information available, right at your fingertips. Download catalogs by product family in PDF format, or view the entire Abbott Vascular inventory in Excel. Product barcodes enable direct scanning for easy reordering.
View Product Catalogs
Absorb GT1 Bioresorbable Vascular Scaffold System
The Absorb GT1 Bioresorbable Vascular Scaffold (BVS) is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
The Absorb GT1 BVS System is contraindicated for use in:
Adverse events that may be associated with PCI, treatment procedures and the use of a coronary scaffold in native coronary arteries include the following, but are not limited to:
AP2946392-WBU Rev. A
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Precautions
Please be sure to read it.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
Are you a healthcare professional?
Test